Galderma Pays $1.5 Billion to Own the Doctor's Office Skincare Shelf

Your daily brief on leadership and business

Galderma has agreed to buy ZO Skin Health for US$1.5 billion in cash, taking full ownership of a brand sold mostly through dermatologists, medical spas and online physician accounts. The sellers include funds managed by Blackstone Tactical Opportunities and the Obagi family. Galderma will pay with a mix of existing cash and bank financing, and expects the deal to close in the fourth quarter of 2026 or early 2027, once regulators sign off.

The price works out to roughly 4.5 times ZO's net sales of about US$330 million over the twelve months to June 2026. ZO, founded in 2007 by dermatologist Dr. Zein Obagi, offers more than 40 products, from cleansers to serums, and is sold through over 16,500 accounts in more than 40 countries. Blackstone bought the business in 2020 and, according to the coverage, has more than doubled its revenue since then, so the seller is not walking away empty-handed.

Retinol meets peptides

The strategic logic is about filling gaps rather than adding duplicates. Galderma already owns Alastin Skincare, whose peptide-based products are used before and after procedures. ZO brings retinol- and acid-based daily routines. According to Kline + Co figures cited in the coverage, the two brands together hold 19% of the US physician skin care category, up from 12.7%. In other words, the patient who walks out of a clinic with a bag of products is now more likely to be carrying Galderma's logo, whatever the regimen.

CEO Flemming Ørnskov called the purchase another step toward building "the world's most innovative dermatology portfolio," and said Galderma sees room to reignite ZO's growth through investment in innovation and commercial reach.

America first, margins later

The US is already Galderma's biggest market: it generated US$1.37 billion, nearly 44% of first-half sales, which grew 32.3% year on year. The company opened a US and Latin America headquarters in Miami in August. Investors should not expect an instant boost to profitability, though. Galderma says the deal will slightly dilute its core EBITDA margin in 2027 as it ramps up commercial spending, with margins expected to return to the group average from 2028. Beauty, it turns out, still takes a little patience.